PSNL Personalis Inc.

28.17
+0.64  (+2%)
Previous Close 27.53
Open 27.68
52 Week Low 4.27
52 Week High 32.8
Market Cap $1,096,737,117
Shares 38,932,805
Float 26,678,537
Enterprise Value $876,956,121
Volume 1,199,466
Av. Daily Volume 748,484
Stock charts supplied by TradingView

Latest News

  1. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.

    The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.

    ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.

    NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the EACR Liquid Biopsies Virtual Event, November 18-19, including a poster presentation and satellite symposia.

    The company will showcase both their platforms, ImmunoID NeXT™ and NeXT Liquid Biopsy™.

    ImmunoID NeXT is the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample, thus maximizing the biological information that can be generated from a precious tumor specimen.

    NeXT Liquid Biopsy, a first-of-its-kind, high-performance exome-wide liquid biopsy assay, provides a unique ability to evaluate the cancer ecosystem and advance the development of next-generation therapies. While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies has demonstrated there can be more to a cancer's genotypic profile than that found in a single tissue biopsy. Therefore, the combination of NeXT Liquid Biopsy and ImmunoID NeXT delivers the most comprehensive view of a cancer's mutational landscape by evaluating both the tissue and blood. NeXT Liquid Biopsy enables investigation into key applications such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. In this presentation, we'll highlight data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of reference standards and patient samples.

    Following are details for the Personalis presentations.

    Scientific Poster Presentation

    Poster Number

     

    Title & Presenter

     

    Dates

    40

     

     

    Sensitive detection and monitoring of genetic alterations in circulating cfDNA with an enhanced whole-exome approach

    Presenter: Simo V. Zhang, PhD

     

    NOV 18-19 | Online

    Following are details of an industry-sponsored symposium which will be presented at the meeting.

    Satellite Symposia

    Title

     

    Title & Presenter

     

    Dates

    Sponsored Symposia

     

    NeXT Liquid Biopsy, A High Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics

    Presenters: Erin N. Newburn, PhD and Dan Norton, MBA

     

    NOV 18-19 | On Demand

    About Personalis, Inc.

    Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    Forward-Looking Statements

    All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis' services for the VA MVP, the company's business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis' filings with the U.S. Securities and Exchange Commission, including the company's most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Personalis disclaims any obligation to update such forward-looking statements.

    View Full Article Hide Full Article
  2. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting from Nov 16-20, 2020.

    The poster presentation, titled "An exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy" will be presented on Tuesday, Nov 17th between 1-2pm EST. The NeXT Dx test utilizes Personalis' ImmunoID NeXT Platform®, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test provides a diagnostic report to the ordering provider which…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that the company will present data from its clinical test - NeXT DxTM - at the virtual AMP Annual Meeting from Nov 16-20, 2020.

    The poster presentation, titled "An exome and transcriptome based NeXT DxTM test enables therapy selection for cancer patients and offers insights into emerging composite biomarkers for immunotherapy" will be presented on Tuesday, Nov 17th between 1-2pm EST. The NeXT Dx test utilizes Personalis' ImmunoID NeXT Platform®, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The Personalis NeXT Dx Test provides a diagnostic report to the ordering provider which includes genomic alterations identified in 247 cancer-related genes, therapy recommendations, clinical trial matching and results from immunotherapy-related biomarkers such as microsatellite instability (MSI) status and exome-wide tumor mutational burden (TMB). Research data supporting identification of novel biomarkers from tumor exome and transcriptome can be provided upon physician's request.

    About Personalis, Inc.

    Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing our biopharmaceutical customers with information on approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    Forward-Looking Statements

    All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the ImmunoID NeXT Platform, Personalis' services for the VA MVP, the company's business opportunities, leadership or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis' filings with the U.S. Securities and Exchange Commission, including the company's most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption "Risk Factors." Personalis disclaims any obligation to update such forward-looking statements.

    View Full Article Hide Full Article
  3. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11th – 13th.

    The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

    Following is a list of abstracts that…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the company will participate in the Society for Immunotherapy of Cancer (SITC) Annual Meeting online, November 11-14, including poster presentations on November 11th – 13th.

    The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.

    Following is a list of abstracts that will be presented at the meeting.

    Scientific Poster Presentations

    Poster Number & Category

    Title & Presenter

    Day & Time

    29

    Biomarkers, Immune Monitoring, and Novel Technologies

    Profiling Tumor Circulating Cell-Free DNA with an Enhanced Whole-Exome to Enable Sensitive Assessment of Somatic Mutations

    Presenter: Simo V. Zhang, PhD

    NOV 11 | 5:15 – 5:45 PM EST

    and

    NOV 13 | 4:40 – 5:10 PM EST

    57

    Biomarkers, Immune Monitoring, and Novel Technologies

    Precision neoantigen discovery using novel algorithms and expanded HLA-ligandome datasets

    Presenter: Dattatreya Mellacheruvu, PhD

    NOV 11 | 5:15 – 5:45 PM EST

    and

    NOV 13 | 4:40 – 5:10 PM EST

    67

    Biomarkers, Immune Monitoring, and Novel Technologies

    B-cell receptor heavy chain repertoire profiling using an augmented transcriptome

    Presenter: Eric Levy, Ph.D.

    NOV 11 | 5:15 – 5:45 PM EST

    and

    NOV 13 | 4:40 – 5:10 PM EST

    73

    Biomarkers, Immune Monitoring, and Novel Technologies

    Orthogonally and functionally validated algorithm for detecting HLA loss of heterozygosity

    Presenter: Rachel M. Pyke, PhD

    NOV 11 | 5:15 – 5:45 PM EST

    and

    NOV 13 | 4:40 – 5:10 PM EST

    Following are details of an industry-sponsored symposium which will be presented at the meeting.

    Industry Sponsor Symposium

    Presentation Category

    Title & Presenter

    Day & Time

    Sponsored Symposia

    Maximizing immunotherapy biomarker discovery with a multidimensional tumor immunogenomics platform

    Presenter: Erin N. Newburn, PhD

    NOV 12 | 12:30 – 12:50 PM EST

     

    Personalis will also be exhibiting during the online conference. Representatives will be available to answer questions about the company's cancer immunogenomics services.

    About Personalis, Inc.

    Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP). In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

     

    View Full Article Hide Full Article
  4. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020.

    Third Quarter Highlights

    • Reported record revenues of $19.8 million in the third quarter of 2020 versus $17.2 million in the third quarter of 2019, an increase of 15.5%
    • A total of 39 customers have placed orders for NeXT as of September 30, 2020, with 7 of those customers placing their first orders in the third quarter of 2020
    • Received a new task order with an approximate value of up to $31 million from U.S. Department of Veterans Affairs Million Veterans Program (VA MVP), increasing the contracted to date value to approximately $175 million
    • Achieved milestone…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for population sequencing and cancer, today reported financial results for the third quarter ended September 30, 2020.

    Third Quarter Highlights

    • Reported record revenues of $19.8 million in the third quarter of 2020 versus $17.2 million in the third quarter of 2019, an increase of 15.5%
    • A total of 39 customers have placed orders for NeXT as of September 30, 2020, with 7 of those customers placing their first orders in the third quarter of 2020
    • Received a new task order with an approximate value of up to $31 million from U.S. Department of Veterans Affairs Million Veterans Program (VA MVP), increasing the contracted to date value to approximately $175 million
    • Achieved milestone of completing more than 90,000 whole human genomes sequenced under the VA MVP contract
    • Completed a follow-on public offering and sold 6.6 million shares of common stock at a price of $19.00 per share; received net proceeds of $117.1 million after discounts, fees, and expenses

    "I'm proud to say that we were able to report record revenues once again this quarter, with our team delivering strong execution across both our population sequencing and biopharma businesses, despite the impact from the COVID-19 pandemic. We continued to see strong ordering levels from both our existing and new customers, and year-to-date, our biopharma orders were twice the amount compared with last year," said John West, Chief Executive Officer. "In addition, we further strengthened our balance sheet by raising $117.1 million with an equity financing in the quarter."

    Third Quarter 2020 Financial Results

    Revenues were $19.8 million in the three months ended September 30, 2020, up 15.5% from $17.2 million in the same period of the prior year. In the third quarter, the VA MVP accounted for $14.1 million of the company's total revenues, and the remaining $5.7 million was from biopharmaceutical and all other customers.

    Gross margin was 26.9% for the three months ended September 30, 2020, compared with 32.8% in the same period of the prior year.

    Operating expenses were $15.0 million for the three months ended September 30, 2020, compared with $11.4 million in the same period of the prior year.

    Net loss was $9.5 million for the three months ended September 30, 2020 and net loss per share was $0.27 based on a weighted-average basic and diluted share count of 35.5 million, compared with a net loss of $6.9 million and a net loss per share of $0.22 based on a weighted-average basic and diluted share count of 31.1 million in the same period of the prior year.

    Cash, cash equivalents, and short-term investments were $206.1 million as of September 30, 2020.

    Guidance and COVID-19

    Due to continued uncertainty surrounding the COVID-19 pandemic, Personalis will not provide guidance for fiscal 2020 at this time.

    Webcast and Conference Call Information

    Personalis will host a conference call to discuss the third quarter financial results after market close on Thursday, November 5, 2020 at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time. The conference call can be accessed live over the phone (866) 220-8061 for U.S. callers or (470) 495-9168 for international callers, using conference ID: 9697771. The live webinar can be accessed at https://investors.personalis.com.

    About Personalis, Inc.

    Personalis, Inc. is a leader in population sequencing and cancer genomics company, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "hope," "intend," "may," "might," "objective," "ongoing," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks, uncertainties and other factors relate to, among others: the timing and pace of new orders from customers; the launch of new products and product features; the timing of tissue and blood sample receipts from customers, which can materially impact revenue quarter over quarter and year over year; whether orders for the NeXT platform and revenues from biopharmaceutical customers will increase; the success of Personalis' collaborations and partnerships; the success of the company's international expansion plans; the evolution of cancer therapies and market adoption of the company's services; the company's expectations regarding future performance; and the COVID-19 pandemic, which may significantly impact the company's business and operations and the business and operations of our customers. In addition, other potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, those risks and uncertainties included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Quarterly Report on Form 10-Q for the period ended September 30, 2020, that will be filed following this earnings release. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

    PERSONALIS, INC.

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

    (in thousands, except share and per share data)

     

     

     

    Three Months Ended

     

     

    Nine Months Ended

     

     

     

    September 30,

     

     

    September 30,

     

     

     

    2020

     

     

    2019

     

     

    2020

     

     

    2019

     

    Revenues

     

    $

    19,816

     

     

    $

    17,153

     

     

    $

    58,472

     

     

    $

    47,053

     

    Costs and expenses

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Costs of revenues

     

     

    14,483

     

     

     

    11,524

     

     

     

    44,428

     

     

     

    31,538

     

    Research and development

     

     

    7,193

     

     

     

    5,303

     

     

     

    20,048

     

     

     

    15,045

     

    Selling, general and administrative

     

     

    7,793

     

     

     

    6,056

     

     

     

    22,772

     

     

     

    15,692

     

    Total costs and expenses

     

     

    29,469

     

     

     

    22,883

     

     

     

    87,248

     

     

     

    62,275

     

    Loss from operations

     

     

    (9,653

    )

     

     

    (5,730

    )

     

     

    (28,776

    )

     

     

    (15,222

    )

    Interest income

     

     

    117

     

     

     

    756

     

     

     

    873

     

     

     

    1,040

     

    Interest expense

     

     

     

     

     

    (204

    )

     

     

    (2

    )

     

     

    (1,133

    )

    Loss on debt extinguishment

     

     

     

     

     

    (1,704

    )

     

     

     

     

     

    (1,704

    )

    Other (expense) income, net

     

     

    (4

    )

     

     

    (2

    )

     

     

    5

     

     

     

    (1,415

    )

    Loss before income taxes

     

     

    (9,540

    )

     

     

    (6,884

    )

     

     

    (27,900

    )

     

     

    (18,434

    )

    Provision for income taxes

     

     

    (5

    )

     

     

    (1

    )

     

     

    (39

    )

     

     

    (5

    )

    Net loss

     

    $

    (9,545

    )

     

    $

    (6,885

    )

     

    $

    (27,939

    )

     

    $

    (18,439

    )

    Net loss per share, basic and diluted

     

    $

    (0.27

    )

     

    $

    (0.22

    )

     

    $

    (0.85

    )

     

    $

    (1.35

    )

    Weighted-average shares outstanding, basic and diluted

     

     

    35,460,092

     

     

     

    31,133,683

     

     

     

    32,845,583

     

     

     

    13,613,444

     

    PERSONALIS, INC.

    SUPPLEMENTAL REVENUE INFORMATION (unaudited)

    (in thousands)

     

     

     

    Three Months Ended

    September 30,

     

     

    Nine Months Ended

    September 30,

     

     

     

    2020

     

     

    2019

     

     

    2020

     

     

    2019

     

    VA MVP

     

    $

    14,092

     

     

    $

    12,912

     

     

    $

    43,598

     

     

    $

    29,791

     

    All other customers

     

     

    5,724

     

     

     

    4,241

     

     

     

    14,874

     

     

     

    17,262

     

    Total

     

    $

    19,816

     

     

    $

    17,153

     

     

    $

    58,472

     

     

    $

    47,053

     

    PERSONALIS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)

    (in thousands, except share and per share data)

     

     

     

    September 30,

     

     

    December 31,

     

     

     

    2020

     

     

    2019

     

    Assets

     

     

     

     

     

     

     

     

    Current assets

     

     

     

     

     

     

     

     

    Cash and cash equivalents

     

    $

    133,245

     

     

    $

    55,046

     

    Short-term investments

     

     

    72,818

     

     

     

    73,243

     

    Accounts receivable, net

     

     

    5,903

     

     

     

    3,300

     

    Inventory and other deferred costs

     

     

    6,268

     

     

     

    4,606

     

    Prepaid expenses and other current assets

     

     

    5,359

     

     

     

    3,383

     

    Total current assets

     

     

    223,593

     

     

     

    139,578

     

    Property and equipment, net

     

     

    12,735

     

     

     

    14,106

     

    Operating lease right-of-use assets

     

     

    10,632

     

     

     

    1,845

     

    Other long-term assets

     

     

    1,852

     

     

     

    1,762

     

    Total assets

     

    $

    248,812

     

     

    $

    157,291

     

    Liabilities and Stockholders' Equity

     

     

     

     

     

     

     

     

    Current liabilities

     

     

     

     

     

     

     

     

    Accounts payable

     

    $

    6,514

     

     

    $

    7,337

     

    Accrued and other current liabilities

     

     

    8,797

     

     

     

    6,648

     

    Contract liabilities

     

     

    20,593

     

     

     

    35,977

     

    Total current liabilities

     

     

    35,904

     

     

     

    49,962

     

    Long-term operating lease liabilities

     

     

    8,897

     

     

     

    639

     

    Other long-term liabilities

     

     

    471

     

     

     

     

    Total liabilities

     

     

    45,272

     

     

     

    50,601

     

    Commitments and Contingencies

     

     

     

     

     

     

     

     

    Stockholders' equity

     

     

     

     

     

     

     

     

    Preferred stock, $0.0001 par value — 10,000,000 shares authorized; none issued

     

     

     

     

     

     

    Common stock, $0.0001 par value — 200,000,000 shares authorized; 38,790,189 and 31,243,029 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

     

     

    4

     

     

     

    3

     

    Additional paid-in capital

     

     

    372,027

     

     

     

    247,282

     

    Accumulated other comprehensive income (loss)

     

     

    37

     

     

     

    (6

    )

    Accumulated deficit

     

     

    (168,528

    )

     

     

    (140,589

    )

    Total stockholders' equity

     

     

    203,540

     

     

     

    106,690

     

    Total liabilities and stockholders' equity

     

    $

    248,812

     

     

    $

    157,291

     

     

    View Full Article Hide Full Article
  5. Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.

    • 29th Annual Credit Suisse Virtual Healthcare Conference
      Presenting on Tuesday, November 10, 2020 at 4:15 p.m. Eastern Time
    • Oppenheimer Fall MedTech Summit
      Participating on Thursday, November 12, 2020

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical…

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for cancer, today announced that company management will participate in the following upcoming investor conferences.

    • 29th Annual Credit Suisse Virtual Healthcare Conference

      Presenting on Tuesday, November 10, 2020 at 4:15 p.m. Eastern Time
    • Oppenheimer Fall MedTech Summit

      Participating on Thursday, November 12, 2020

    About Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient's cancer and immune response. The Personalis® ImmunoID NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue or blood sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over two million veteran genomes. The Personalis Clinical Laboratory is GxP aligned as well as CLIA'88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

    View Full Article Hide Full Article
View All Personalis Inc. News